Epitope

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

Retrieved on: 
Mittwoch, Mai 8, 2024
FDA, CFO, Research, CRC, Partnership, PDAC, ASCO, CD137, AACR, Biomarker, EGFR, Lung cancer, Non-small-cell lung cancer, Drug design, Illinois State University, HER2, Food, Bristol Myers Squibb, Patent, Eli Lilly and Company, BLA, NRG1, Therapy, NSCLC, PYC, Safety, Cetuximab, Pembrolizumab, Marketing, Clinical trial, CD3, MET, HNSCC, Gilead Sciences, Betta, Epitope, Biologics license application, Patient, Antigen, Head, Pharmaceutical industry

Merus plans to provide updated efficacy, durability and safety data of this cohort in the second half of 2024.

Key Points: 
  • Merus plans to provide updated efficacy, durability and safety data of this cohort in the second half of 2024.
  • In 2024, Merus is planning to initiate the evaluation of petosemtamab with standard chemotherapy in 2L CRC.
  • During the first quarter of 2024, Merus achieved a milestone of $1 million for candidate nomination and expects to receive payment in the second quarter of 2024.
  • In March 2024, Merus and Gilead Sciences announced a collaboration to discover novel antibody based trispecific T-cell engagers using Merus’ patented Triclonics® platform.

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
Mittwoch, Mai 8, 2024
Research, Finance, Clinical Trials, Professional Services, Cardiology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Amyloid, Mortality, FDA, License, Fast Track, TTR, ATTR, Organ dysfunction, Risk, Food, Amyloidosis, Orphan, Epitope, Partnership, IND, Roche, Culture, Therapy, Novo Nordisk, Patient, Acquisition, Failure, VITAL, Bristol Myers Squibb, Clinical trial, European Medicines Agency, Overalls, Pharmaceutical industry

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2024 and provided business highlights.

Key Points: 
  • Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2024 and provided business highlights.
  • For the first quarter of 2024, Prothena reported a net loss of $72.2 million, as compared to a net loss of $46.9 million for the first quarter of 2023, respectively.
  • Prothena reported total revenue of $0.1 million for the first quarter of 2024, as compared to total revenue of $2.2 million for the first quarter of 2023.
  • Research and development (R&D) expenses totaled $64.1 million for the first quarter of 2024, as compared to $44.8 million for the first quarter of 2023.

Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases

Retrieved on: 
Montag, April 29, 2024
Doctor of Philosophy, Flagship Pioneering, BMY, Epitope, Research, Vaccine, Repertoire, Disease, Autoimmune disease, Patient, Immunology, BMS, Immune system, Bristol Myers Squibb, TCR, Biotechnology, Pharmaceutical industry

CAMBRIDGE, Mass., April 29, 2024 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to develop tolerizing vaccines for up to three autoimmune diseases. The collaboration aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system.

Key Points: 
  • CAMBRIDGE, Mass., April 29, 2024 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to develop tolerizing vaccines for up to three autoimmune diseases.
  • The collaboration aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system.
  • "We are excited to collaborate with Bristol Myers Squibb to combine their leadership in immunology with our unique ability to discover key disease-associated epitopes in patients with autoimmune diseases.
  • This collaboration enables us to serve patients suffering from autoimmune diseases by translating our DECODE discoveries into potentially transformative medicines that address the underlying cause of their disease."

EQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Retrieved on: 
Freitag, Mai 3, 2024
University, Part, CMO, Federal republic, Research, Cancer, Federal Patent Court (Germany), Vaccine, Business, Webcast, BioNTech, District court, Whole genome sequencing, Vaccination, Public, WHO, Hearing loss, Cardiology, Animal, EP 1, Omicron, GSK, Systems biology, Workforce, Infection, Messenger, Federal court, Therapy, Data monitoring committee, Safety, Monroe Dunaway Anderson, CVAC, Justice, RNA, Astrocytoma, Motion, Human, CureVac, Pandemic, GMP, Sąd rejonowy, SARS-CoV-2, Business development, Epitope, MD, Acuitas Therapeutics, DSMB, Ageing, Patent, Patient, Neurology, Operating cost, H5N1, MD Anderson Cancer Center, PPA, Interim, MBA, Antigen, COVID-19, Amgen

ET / 3 p.m. CET

Key Points: 
  • ET / 3 p.m. CET
    TÜBINGEN, Germany/BOSTON, USA – April 24, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the fourth quarter and full-year 2023 and provided a business update.
  • “We closed out 2023 on a sturdy footing and are poised to advance strongly through 2024 with strategic initiatives to make CureVac fit-for-purpose.
  • Thaminda Ramanayake was appointed to the CureVac Management Team as Chief Business Officer effective June 1, 2024.
  • Mr. Ramanayake joins CureVac from Affini-T Therapeutics, where he served as Chief Business Officer and was responsible for creating the company’s business development organization.

Longhorn Vaccines and Diagnostics to Present Data on LHNVD-105, a Universal Vaccine Candidate, at ECCMID 2024

Retrieved on: 
Donnerstag, April 11, 2024
Health, Infectious Diseases, Research, Pharmaceutical, Science, Biotechnology, Neuraminidase, Infection, Public, University, Gram-positive bacteria, Mycobacterium tuberculosis, Epidemiology, Abstract, ECCMID, Epitope, Vaccine

Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present three abstracts at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2024.

Key Points: 
  • Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present three abstracts at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2024.
  • ECCMID will take place online and in-person in Barcelona, Spain, from April 27-30, 2024.
  • The first two abstracts will detail data on LHNVD-105, an adjuvanted composite peptide universal influenza vaccine, and the monoclonal antibodies it produces.
  • Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)
    Session Title: 10f.

Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024

Retrieved on: 
Donnerstag, April 25, 2024
Infection, Congress, Recombinant antibodies, SARS-CoV-2, Long, Viral, ELISA, ESCMID, Cytokine, Epitope, Lyme disease, Research, ELISpot, Immunology, Diagnosis, Long COVID, Biomarker, Immunity, Flow cytometry, CD8, Vaccine

The Company is hosting at Booth F43, and management will be available for discussions with research organizations and potential partners.

Key Points: 
  • The Company is hosting at Booth F43, and management will be available for discussions with research organizations and potential partners.
  • "We are very pleased to launch ImmuneSelect, an important portfolio of immune profiling solutions within our ViraxImmune™ T-Cell diagnostic platform," commented Mr. James Foster, Chief Executive Officer of Virax Biolabs.
  • "The launch marks a significant milestone for Virax as it brings us a step closer to commercializing ViraxImmune™ as a full In-Vitro-Diagnostic product."
  • ImmuneSelect is the Company's new portfolio of immune profiling solutions dedicated to investigating adaptive immunity.

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Montag, April 8, 2024
Computational biology, Malignancy, Canadian Aviation Regulations, Gene editing, Bone disease, Cell, Hook effect, CXCR4, Enfortumab vedotin, Synthetic biology, Patient, Neoplasm, Epitope, Differentiable function, Ink, PBMC, Protein engineering, HLA, Science, Cytotoxicity, AACR, Phenotype, Therapy, IPSC, Skin, Inflammation, Prognosis, Carcinogenesis, Rejection, CD22, VHH, Poster, NK, Century, Autoimmunity, Bone marrow, Engineering, CD19, Vaccine

PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024.

Key Points: 
  • PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024.
  • This novel CAR was engineered and tested in iPSC-derived gamma-delta T cells, showing in vitro tumor cell cytotoxicity.
  • These findings support the continued examination of a CD19xCD22 bispecific CAR for off-the-shelf allogeneic cell therapy to expand patient access beyond CD19 CAR-T cell therapies.
  • In these preclinical studies, Century identified novel single-domain antibodies (VHH) that bind to multiple epitopes on the NECTIN4 extracellular domain.

Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024

Retrieved on: 
Montag, April 8, 2024
AP, Infection, HIV, Nature Biotechnology, Epitope, Cancer, SARS-CoV-2, Gritstone bio, HLA, AACR, Immunity, EDGE, Poster, Vaccine

EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today presented an update on its T cell epitope discovery platform, EDGE, at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. The presentation details improvements Gritstone has made in prediction of peptide presentation by HLA Class I, associated with CD8+ T cells, since the publication of the initial results in 2018 (Nature Biotechnology). It also reviews how Gritstone has expanded EDGE’s application to predict peptide presentation by HLA Class II.

Key Points: 
  • The presentation details improvements Gritstone has made in prediction of peptide presentation by HLA Class I, associated with CD8+ T cells, since the publication of the initial results in 2018 ( Nature Biotechnology ).
  • It also reviews how Gritstone has expanded EDGE’s application to predict peptide presentation by HLA Class II.
  • “Identifying which of the hundreds of tumor mutations are most likely to serve as neoantigens, key targets of tumor-specific T cells, is critical to the development of effective neoantigen-directed vaccines,” said Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer of Gritstone bio.
  • The improvements we are making to EDGE, leveraging advances in protein large language models and in-house immunopeptidomics, have positioned EDGE as a leading HLA/peptide predictive platform in the neoantigen cancer vaccine field.

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

Retrieved on: 
Freitag, April 5, 2024
CD4, CD8, AMP, Development, Antigen, Immunotherapy, Colorectal cancer, Memory, Patient, Lung, GM-CSF, Biomarker, DNA, Epitope, Cancer, Granzyme B, BRAF, Lymph, IL2, Circulating tumor DNA, Phenotype, Neoplasm, Research and development, Immunization, Therapy, Vaccination, CRC, V600E, Immune system, Melanoma, Granzyme, Phase 1, Amphetamine, Nature Medicine, Annual general meeting, Vaccine

Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared.

Key Points: 
  • Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared.
  • A majority of patients who received the booster immunizations maintained or increased mKRAS-specific T cell responses relative to baseline.
  • The mKRAS-specific CD4 and CD8 T cells generated by ELI-002 exhibited increased cytotoxic function and development of favorable memory phenotype.
  • "Earlier data published in Nature Medicine demonstrate that our off-the-shelf lymph node-targeted cancer vaccine candidate, ELI-002, induces memory T cell responses.

CDR-Life Unveils Results on T-Cell Engagers Targeting Hard-to-Treat Solid Tumors at AACR 2024

Retrieved on: 
Freitag, April 5, 2024
Cell, Trichloroethylene, Patient, Lung, Epitope, Breast, KK, Allele, AACR, Cancer, Antibody, TCE, Therapy, Peptide, Vaccine

Identifying a TCE against the KK-LC-1 peptide on HLA-A*01 will provide an option for patients that do not benefit from the more common HLA-A*02 targeting therapeutics currently in development.

Key Points: 
  • Identifying a TCE against the KK-LC-1 peptide on HLA-A*01 will provide an option for patients that do not benefit from the more common HLA-A*02 targeting therapeutics currently in development.
  • However, high levels of similar off-target peptides presented in healthy tissues make targeting the KK-LC-1/HLA-A*01 challenging.
  • CDR-Life’s data gathered on pMHC TCE antibodies with high specificity towards HLA-A*01 restricted KK-LC-1 epitopes demonstrate the antibodies’ promising anti-tumor activity and specificity for KK-LC-1/HLA-A*01 positive tumors.
  • In vitro studies showed significantly higher TCE-dependent T-cell activation towards cells presenting the target peptide compared to the risk peptides.